GLP-1 receptor agonist discontinuation

GLP-1 receptor agonist discontinuation has been studied in 2 papers since 2026: 1 observational study in people, 1 review; 2 in the past year. The newest story, Nov 10, 2026: “Stopping some diabetes drugs linked to heart events and deaths”.

Exposure

2 papers study it5 findingsUpdated Nov 1, 2026

1 new paper in 30 daysSee all 2 papers on GLP-1 receptor agonist discontinuation

At a glance

The findings reach people, from one lab or study. 1 lab.

“interrupting a therapy with GLP-1RA was associated with a higher risk of a composite of myocardial infarction, stroke, or death from any cause”

GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort studyThe Lancet regional health. Europe2026doi:10.1016/j.lanepe.2026.101881

None of its findings points the other way.

1 lab

Humans1

What did studies of GLP-1 receptor agonist discontinuation find?

Studies of GLP-1 receptor agonist discontinuation measured 2 outcomes: Cardiometabolic risk and body weight.

Cardiometabolic risk

upin humans1

1 study

GLP-1 receptor agonist discontinuation increases cardiometabolic risk in humans.
“Discontinuation is associated with substantial weight regain (60%-90% within one year) and parallel reversal of cardiometabolic benefits.”
Review
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists
Diabetes, obesity & metabolismMar 26, 2026

Body weight

upin humans1

1 study

GLP-1 receptor agonist discontinuation increases body weight in humans (60%-90% weight regain within one year).
“Discontinuation is associated with substantial weight regain (60%-90% within one year)”
Reviewwithin one year
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists
Diabetes, obesity & metabolismMar 26, 2026

What is GLP-1 receptor agonist discontinuation linked with?

Studies link GLP-1 receptor agonist discontinuation with 3 measures: mortality, myocardial infarction, stroke, or all-cause mortality and coronary artery disease.

Mortality

upin humans1HR 4.81

1 study

GLP-1 receptor agonist discontinuation is associated with mortality in humans (Type 2 diabetes without previous cardiovascular disease; compared with continued treatment) (HR 4.81 (95% CI 4.39–5.26); IRR 4.67 (95% CI 4.11–5.30)).
“The IRR for death from any cause was 4.67 (95% CI 4.11–5.30) and the corresponding HR 4.81 (95% CI 4.39–5.26).”
HumansType 2 diabetes without previous cardiovascular disease; compared with continued treatment
Stopping some diabetes drugs linked to heart events and deaths
The Lancet regional health. EuropeNov 1, 2026

Myocardial infarction, stroke, or all-cause mortality

upin humans1HR 2.03

1 study

GLP-1 receptor agonist discontinuation is associated with myocardial infarction, stroke, or all-cause mortality in humans (Type 2 diabetes without previous cardiovascular disease; compared with continued treatment) (HR 2.03 (95% CI 1.92–2.14); IRR 2.01 (95% CI 1.77–2.28)).
“interrupting a therapy with GLP-1RA was associated with a higher risk of a composite of myocardial infarction, stroke, or death from any cause”
HumansType 2 diabetes without previous cardiovascular disease; compared with continued treatment
Stopping some diabetes drugs linked to heart events and deaths
The Lancet regional health. EuropeNov 1, 2026

Coronary artery disease

upin humans1

1 study

GLP-1 receptor agonist discontinuation raises the risk of coronary artery disease in humans (early discontinuation (<1 year) compared with continued therapy).
“Early discontinuation (< 1 year) is associated with increased risks of coronary artery disease and heart failure compared with continued therapy.”
Reviewearly discontinuation (<1 year) compared with continued therapy<1 year
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists
Diabetes, obesity & metabolismMar 26, 2026

Latest

2 papers in 12 months

The Lancet Regional Health EuropeNov 10

Stopping some diabetes drugs linked to heart events and deaths

The combined rate of heart attack, stroke or death was 2.01 times as high among people who stopped treatment as among those who continued.The combined rate of heart attack, stroke or death was 2.01 times as high among people who stopped treatment as among those who continued.

Cohort studyType 2 diabetes